Clinical Trials Search
EDRN Prostate MRI Biomarker Study and Reference Set
This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.
The overarching goal of EDRN protocol is to evaluate whether prostate MRI with other biomarker panel from Urine and serum (PSA, PCA3, TMPRSS2:ERG) will significantly improve specificity (up to 10%) to identify high-grade prostate cancer.